Sale of Ginkor Fort boosts Ipsen's first-half performance
This article was originally published in Scrip
At the end of last month, Ipsenposted encouraging sales and revenue figures for the first half, largely due to a strong performance by its endocrinology and neuromuscular disorder franchises. Each grew by around 20% compared with the same period last year. Total revenues increased by 10.5% to €551.1 million. Ipsen's gastroenterology products also performed well, with sales increasing by 10%.